Research map: An evaluation of the use of the Universal Benefit–Risk Assessment Framework by the Zambia Medicines Regulatory Authority for documenting and communicating benefit–risk decisions.

Back to the article

Papers in this map

  1. Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions · Francesco Pignatti · 2015 · 48 citations · Cited by this paper
  2. In silico prediction of Ames mutagenicity for organosilicon compounds: Exploring and enhancing chemical space boundaries · 2026 · Related
  3. A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward? · Stuart Robert Walker · 2014 · 39 citations · Cited by this paper
  4. Standardization and Assessment of Acute Dermal Toxicity of an Ayurvedic Medicine Brihat Somraji Taila in Sprague-Dawley rats · 2026 · Related
  5. Real‐world evidence to support regulatory decision making: New or expanded medical product indications · Jessica Myers Franklin · 2021 · 36 citations · Cited by this paper
  6. Evaluating dosing guidelines for Ginkgo biloba: An evidence-based approach to standardisation · 2026 · Related
  7. Advancing structured decision‐making in drug regulation at the FDA and EMA · Aris Angelis · 2020 · 34 citations · Cited by this paper
  8. Dietary intake and health risk characterization of cadmium, lead, and mercury in milkfish (Chanos chanos) and tilapia (Oreochromis spp.) from aquaculture farms surrounding Manila bay, Philippines · 2026 · Related
  9. WHO collaborative registration procedure using stringent regulatory authorities’ medicine evaluation: reliance in action? · Alexandra Vaz · 2022 · 32 citations · Cited by this paper
  10. Polycyclic aromatic hydrocarbon (PAH) contamination in clinical nutrition: Levels and associated health risks in enteral nutrition formulas · 2026 · Related
  11. Multi-Criteria Decision Analysis for Benefit-Risk Analysis by National Regulatory Authorities · Orin T. Chisholm · 2022 · 30 citations · Cited by this paper
  12. Automated extraction of toxicological mechanism of action from PubMed literature using Large Language Models · 2026 · Related
  13. Benefit-Risk Assessments at the US Food and Drug Administration · Robert M. Califf · 2017 · 29 citations · Cited by this paper
  14. Derivation of an occupational exposure limit (OEL) for a potent bispecific protein—Blinatumomab (BLINCYTO®) · 2026 · Related
  15. The Benefit-Risk Assessment of Medicines: Experience of a Consortium of Medium-Sized Regulatory Authorities · Neil McAuslane · 2017 · 23 citations · Cited by this paper
  16. Microplastics in intravenous fluids: Occurrence, characterization, and risk indicators · 2026 · Related
  17. Can Standardisation of the Public Assessment Report Improve Benefit-Risk Communication? · Andrea Keyter · 2020 · 11 citations · Cited by this paper
  18. Food enzyme safety: an extensive lineage of safe Aspergillus niger production strains · 2026 · Related
  19. Pharmacovigilance Principles: The Building Blocks of Benefit-Risk Assessments · Rosa Piccirillo · 2022 · 4 citations · Cited by this paper
  20. 40-week repeat-dose toxicity, toxicokinetics, and immunogenicity of efsubaglutide alfa following subcutaneous administration in cynomolgus monkeys · 2026 · Related
  21. Health Technology Agency insights: informing modification of a qualitative benefit risk framework for Health Technology Reassessment of prescription medications · Mary Alison Maloney · 2019 · 3 citations · Cited by this paper
  22. Analysis Considerations for Real-World Evidence and Clinical Trials Related to Safety · Richard C. Zink · 2021 · 2 citations · Cited by this paper
  23. The value of a structured, systematic approach to benefit-risk assessment of medicines: A South African regulator case study · Lorraine Danks · 2025 · 2 citations · Cited by this paper
  24. Mapping the cancer research landscape across Zambia: evidence to support national cancer control planning · Susan Msadabwe · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)